Silence Therapeutics PLC Director/PDMR Shareholding and Additional Listing (8944O)
04 Ottobre 2019 - 06:21PM
UK Regulatory
TIDMSLN
RNS Number : 8944O
Silence Therapeutics PLC
04 October 2019
Director/PDMR Shareholding and Additional Listing
October 4, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the
Company") a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases, today
announces that on October 4, 4,000 Shares were purchased by David
Lemus, Non-Executive Director of the Company, at GBP1.86 per
share.
Mr Lemus has also exercised 1,626 Conditional Share Awards at a
price of 5p per share. Following the exercise and purchase of
shares, David Lemus is interested in 5,626 ordinary shares, being
<0.01% of the enlarged issued share capital of the Company.
The Company also announces it has today issued and allotted
1,626 new ordinary shares of 5p each ("New Ordinary Shares")
following this exercise of share options under the 2018
Non-Employee Long Term Incentive Plan. Application will be made to
the London Stock Exchange for the New Ordinary Shares to be
admitted to trading on AIM. Admission is expected to be effective
on October 10, 2019. The New Ordinary Shares shall rank pari passu
with the existing ordinary shares in the Company.
The total number of ordinary shares of 5p each in issue,
following admission of the New Ordinary Shares, will be 78,327,279.
The Company holds no shares in Treasury. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name David Lemus
--------------------------- ----------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- ----------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- ----------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- ----------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- ----------------------------------------------
b) Nature of the transaction Exercise of Conditional Share Options
over Ordinary Shares in Silence Therapeutics
plc
Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- ----------------------------------------------
c) Prices(a) and volume(s) Exercise Price Volume
GBP0.05 1,626
-------
Purchase Price Volume
GBP1.86 4,000
-------
--------------------------- ----------------------------------------------
d) Aggregated information
- Aggregated volume 5,626 Ordinary Shares
- Price GBP7,521.30
--------------------------- ----------------------------------------------
e) Date of the transaction 04 October 2019
--------------------------- ----------------------------------------------
f) Place of the transaction Exercise - Outside a trading venue
Purchase - London Stock Exchange, AIM
--------------------------- ----------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Dr David Horn Solomon, Chief Executive Officer 6900
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its
proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional
level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's
proprietary RNA chemistries and
delivery systems are designed to improve the stability of our
molecules and enhance effective delivery
to target cells, providing a powerful modular technology well
suited to tackle life-threatening diseases.
For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEAKELEFPNFFF
(END) Dow Jones Newswires
October 04, 2019 12:21 ET (16:21 GMT)
Grafico Azioni Silence Therapeutics (LSE:SLN)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Silence Therapeutics (LSE:SLN)
Storico
Da Mar 2023 a Mar 2024